Sentigen files agreement with Merck

By Elaine Rigoli

Tampa, Fla., May 15 - Sentigen Holding Corp., through its wholly owned subsidiary, Cell & Molecular Technologies, Inc. (CMT) has entered into a laboratory services agreement with Merck & Co., Inc., effective April 1 for a one-year term.

Sentigen, through CMT, will provide Merck with cell banking to Merck for its high-throughput screening program. Payments by Merck to CMT under the agreement are made in accordance with a formula based upon the costs of the high-throughput screening program, including direct material and labor costs and certain overhead, in addition to the payment of certain incentives and profits.

Located in Phillipsburg, N.J., Sentigen is holding company conducting business through two wholly owned operating subsidiaries, CMT and Sentigen Biosciences.

CMT provides contract research and development services and manufactures specialty cell culture media, reagents and other research products for companies engaged in the drug-discovery process.

Merck is a global research-driven pharmaceutical company located in Whitehouse Station, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.